Clinical Scorecard: Combination Therapy Shows Potential in Psoriasis, Obesity

At a Glance

Key Highlights

• 27% of participants on combination therapy achieved complete skin clearance and weight reduction vs 6% on ixekizumab alone
• Significant improvements in PASI scores and weight reduction with combination therapy
• 84% of participants completed treatment through week 36
• Gastrointestinal events more common in combination therapy group
• No new safety concerns reported

Guideline-Based Recommendations

Diagnosis

• Evaluate for moderate to severe plaque psoriasis with PASI of 12 or greater
• Assess for overweight or obesity with at least one weight-related comorbidity

Management

• Consider ixekizumab plus tirzepatide for patients not responding to monotherapy
• Individualized diet and exercise counseling recommended

Monitoring & Follow-up

• Monitor for treatment-emergent adverse events, particularly gastrointestinal symptoms
• Assess cardiometabolic measures regularly

Risks

• Increased incidence of gastrointestinal events with combination therapy
• Serious adverse events occurred in 4% of combination therapy group

Patient & Prescribing Data

Adults with moderate to severe plaque psoriasis and overweight or obesity

Combination therapy shows superior efficacy in achieving weight loss and skin clearance

Clinical Best Practices

• Utilize combination therapy for enhanced treatment outcomes in eligible patients
• Ensure regular follow-up to monitor efficacy and adverse effects
• Educate patients on potential gastrointestinal side effects

Related Resources & Content

• JAMA Dermatology